CAS#:1415456-99-3
Cagrilintide
Size
Research Profile
Cagrilintide
Literature-based research context for laboratory reference only.
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. Research explores its complementary mechanism to GLP-1 agonism for additive weight reduction, with trials showing enhanced satiety signaling via area postrema and dorsal vagal complex.
Selected literature
- Enebo et al., 2021, Lancet.
- Lau et al., 2021, Journal of Medicinal Chemistry.
This page is provided for laboratory reference and literature review only. The material is not presented as a consumer product, medical treatment, diagnostic tool, or recommendation for human or animal use.
Overview
Cagrilintide is presented here as a laboratory reference entry. The Research Profile summarizes literature-based biological context, while this Overview documents the identity record, specification set, preparation format, and quality-reference information available on the page.
The identity block lists CAS number 1415456-99-3, molecular formula C₁₆₇H₂₆₇N₄₅O₅₂, and molecular weight 3,756.2 Da. The material record is paired with ≥99% purity information and a lyophilized presentation for reference review.
Available specification labels include 5mg and 10mg. The active selection is 5mg; changing the selector updates the visible specification label and COA lot references while preserving the same research-reference context.
For the active selection, the page currently shows 1 active COA lot reference. COA links, when present, are retained for batch-level purity, identity, and quantity review, while packaging and storage details remain separated in Structure & Identity.